Compare · CGC vs MTCR
CGC vs MTCR
Side-by-side comparison of Canopy Growth Corporation (CGC) and Metacrine Inc. (MTCR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CGC and MTCR operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- CGC is the larger of the two at $2.86B, about 131.5x MTCR ($21.8M).
- CGC has hit the wire 3 times in the past 4 weeks while MTCR has been quiet.
- CGC has more recent analyst coverage (19 ratings vs 4 for MTCR).
- Company
- Canopy Growth Corporation
- Metacrine Inc.
- Price
- $0.94-1.93%
- $0.49-0.50%
- Market cap
- $2.86B
- $21.8M
- 1M return
- -3.27%
- -
- 1Y return
- -15.75%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 3
- 0
- Recent ratings
- 19
- 4
Canopy Growth Corporation
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flowers, oils and concentrates, and softgel capsules. It offers its products under the Tweed, Quatreau, Deep Space, Spectrum Therapeutics, First & Free, TWD, This Works, BioSteel, DNA Genetics CraftGrow, Tokyo Smoke, DOJA, Van der Pop, and Bean & Bud brands. The company also provides growth capital and a strategic support platform that pursues investment opportunities in the global cannabis sector. Canopy Growth Corporation has a clinical research partnership with NEEKA Health Canada and NHL Alumni Association to examine the efficacy of CBD-based therapies as part of the mitigation of persistent post-concussion symptoms. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.
Metacrine Inc.
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases. It is developing MET409 that has completed Phase 1b proof-of-concept clinical trial for the treatment of patients with non-alcoholic steatohepatitis (NASH); and is in Phase 2a clinical trial in combination with empagliflozin for the treatment of patients with type 2 diabetes mellitus and NASH. The company also develops MET642, which is in Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis patients. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Latest CGC
- Canopy Growth to Report First Quarter Fiscal 2027 Financial Results on August 7, 2026
- Canopy Growth Announces Participation at Upcoming Canaccord Genuity Growth Conference
- SEC Form PRE 14A filed by Canopy Growth Corporation
- Director Bayern Joseph sold $2,953 worth of shares (3,197 units at $0.92), decreasing direct ownership by 2% to 145,127 units (SEC Form 4) (withholding tax)
- Director Yanofsky Theresa sold $13,905 worth of shares (15,054 units at $0.92), decreasing direct ownership by 9% to 146,415 units (SEC Form 4) (withholding obligation)
- Director Atkins M Shan sold $2,953 worth of shares (3,197 units at $0.92), decreasing direct ownership by 2% to 146,517 units (SEC Form 4) to cover taxes
- Director Lazzarato David Angelo sold $20,944 worth of shares (22,674 units at $0.92), decreasing direct ownership by 10% to 211,859 units (SEC Form 4) to cover withholding tax
- Director Atkins M Shan was granted 108,324 shares, increasing direct ownership by 262% to 149,714 units (SEC Form 4)
- Director Lazzarato David Angelo was granted 162,485 shares, increasing direct ownership by 226% to 234,533 units (SEC Form 4)
- Director Bayern Joseph was granted 108,324 shares, increasing direct ownership by 271% to 148,324 units (SEC Form 4)
Latest MTCR
- SEC Form 15-12G filed by Metacrine Inc.
- Metacrine Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Leadership Update, Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Klassen Preston
- SEC Form S-8 POS filed by Metacrine Inc.
- SEC Form S-8 POS filed by Metacrine Inc.
- Metacrine Inc. filed SEC Form 8-K: Leadership Update
- Metacrine Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets
- SEC Form EFFECT filed by Metacrine Inc.
- SEC Form 25-NSE filed by Metacrine Inc.
- SEC Form SC 13G/A filed by Metacrine Inc. (Amendment)